Cargando…

COVID-19 vaccine inequity in African low-income countries

Equitable access and utilization of the COVID-19 vaccine is the main exit strategy from the pandemic. This paper used proceedings from the Second Extraordinary Think-Tank conference, which was held by the Health Economics and Policy Unit at the Kamuzu University of Health Sciences in collaboration w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunyenje, Chifundo Annessia, Chirwa, Gowokani Chijere, Mboma, Sebastian M., Ng'ambi, Wingston, Mnjowe, Emmanuel, Nkhoma, Dominic, Ngwira, Lucky Gift, Chawani, Marlen Stacey, Chilima, Ben, Mitambo, Collins, Crampin, Amelia, Mfutso-Bengo, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025287/
https://www.ncbi.nlm.nih.gov/pubmed/36950103
http://dx.doi.org/10.3389/fpubh.2023.1087662
Descripción
Sumario:Equitable access and utilization of the COVID-19 vaccine is the main exit strategy from the pandemic. This paper used proceedings from the Second Extraordinary Think-Tank conference, which was held by the Health Economics and Policy Unit at the Kamuzu University of Health Sciences in collaboration with the Malawi Ministry of Health, complemented by a review of literature. We found disparities in COVID-19 vaccine coverage among low-income countries. This is also the case among high income countries. The disparities are driven mainly by insufficient supply, inequitable distribution, limited production of the vaccine in low-income countries, weak health systems, high vaccine hesitancy, and vaccine misconceptions. COVID-19 vaccine inequity continues to affect the entire world with the ongoing risks of emergence of new COVID-19 variants, increased morbidity and mortality and social and economic disruptions. In order to reduce the COVID-19 vaccination inequality in low-income countries, there is need to expand COVAX facility, waive intellectual property rights, transform knowledge and technology acquired into vaccines, and conduct mass COVID-19 vaccination campaigns.